Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
Estradurin (polyestradiol phosphate) is an injectable estrogen replacement therapy approved in 1957 for hormone-related indications. It is a long-acting estrogen ester administered via intramuscular injection. Specific therapeutic indications are not fully detailed in available data, but the product targets patients requiring sustained estrogen replacement.
With LOE approaching and minimal current linked roles (0 jobs), this legacy injectable faces significant market contraction; commercial teams are likely in maintenance mode with reduced headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Estradurin presents limited career opportunity with zero currently linked jobs; working on this product would be a defensive, short-term assignment on a legacy injectable in final market phase. Career growth is constrained due to declining commercial activity and imminent LOE, making this role better suited for managing decline rather than building expertise in growing therapeutic areas.
Worked on ESTRADURIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.